David D . Ho Aaron Diamond AIDS Research Center Columbia University SARS - CoV - 2 Variants of Concern David D . Ho Aaron Diamond AIDS Research Center Columbia University Vagelos College of Physicians and Surgeons Modified from Economist UK SA NY BZ Resistance of B . 1 . 1 . 7 ( UK ) and B . 1 . 351 ( SA ) to select monoclonal antibodies To t a l = 1273 LegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegend NTD RBD SD1 SD2 FP HR1 CH CT HR2 1 14 306 331 528 591 686 816 910 985 1035 1068 1163 1211 1273 S1 S2 SA L18F UK 69 - 70del 144del N501Y A570D P681H T716I S982A D1118H D80A D215G 242 - 244del R246I K417N E484K N501Y CD S2’ S1 / S2 A701V Inner side Outer side ACE2 binding site “UP” RBD Top view of spike NTD NTD NTD NTDsupersite Outer side view E484 2 - 7 REGN10987 1 - 57 C135 S309 N501 K417 E484 2 - 36COVA1 - 16 910 - 30 2 - 15 REGN10933 C121 LY - CoV555 E484 K417 N501 135 ° 90 ° Inner side view RBM view “Down” RBD 2 - 36 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 - 20 0 20 40 60 80 100 WA1B . 1 . 1 . 7 B . 1 . 351 COVA1 - 16 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 910 - 30 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 2 - 15 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 LY - CoV555 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 - 20 0 20 40 60 80 100 C121 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 REGN10933 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 2 - 7 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 REGN10987 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 - 20 0 20 40 60 80 100 C135 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 S309 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 1 - 57 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 % N e u t r a li z a t i on Antibody (  g / mL ) 5 - 24 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 - 20 0 20 40 60 80 100 WA1B . 1 . 1 . 7 B . 1 . 351 4 - 8 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 4A8 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 2 - 17 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 4 - 19 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 - 20 0 20 40 60 80 100 5 - 7 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 Antibody (  g / mL ) % N e u t r a li z a t i on 69 - 70 Y144 R246 242 - 244 5 - 24 4A84 - 8 NTD supersite Wang et al , Nature 2021 Red : resistance > 3 fold ; Green : sensitization > 3 fold Susceptibility of B . 1 . 1 . 7 and B . 1 . 351 & mutant pseudoviruses to neutralization by RBD and NTD mAbs ( fold change in IC50 ) Fold Change of IC50 from WT RBD - directed mAbs NTD - directed mAbs Inner side RBM Outer side Supersite Others 2 - 36 COVA1 - 16 910 - 30 2 - 15 LY - CoV555 C121 REGN10933 2 - 7 REGN10987 C135 S309 1 - 57 5 - 24 4 - 8 4A8 2 - 17 4 - 19 5 - 7 UK B . 1 . 1 . 7 3 . 4 3 . 4 - 10 . 3 - 3 . 0 - 2 . 8 4 . 0 1 . 0 1 . 5 1 . 0 3 . 0 - 4 . 0 - 1 . 5 - 330 . 2 < - 1000 < - 1000 - 42 . 6 - 29 . 2 - 7 . 5 UKΔ8 1 . 2 1 . 3 - 14 . 0 2 . 2 1 . 7 2 . 3 2 . 5 1 . 4 2 . 1 - 1 . 4 - 3 . 1 2 . 1 < - 1000 < - 1000 < - 1000 - 121 . 2 - 20 . 5 - 11 . 9 69 - 70del - 1 . 0 1 . 1 2 . 7 1 . 2 1 . 1 1 . 7 1 . 3 - 1 . 2 1 . 2 1 . 8 - 1 . 6 1 . 1 1 . 1 1 . 1 1 . 5 - 1 . 1 - 3 . 6 - 4 . 0 144del 1 . 5 - 1 . 3 2 . 3 1 . 3 1 . 1 1 . 7 1 . 3 1 . 2 - 1 . 4 1 . 4 1 . 4 1 . 1 < - 1000 < - 1000 < - 1000 - 80 . 7 1 . 6 - 3 . 7 N501Y - 1 . 2 - 1 . 4 - 12 . 7 1 . 5 - 1 . 0 1 . 5 - 1 . 4 - 1 . 0 1 . 3 1 . 2 1 . 2 3 . 6 - 2 . 9 - 6 . 7 MPI↓ - 12 . 0 - 1 . 4 - 3 . 2 A570D 4 . 1 1 . 9 6 . 7 1 . 4 1 . 7 1 . 7 4 . 7 - 2 . 3 - 1 . 6 1 . 1 - 1 . 2 2 . 2 1 . 1 - 15 . 1 - 2 . 9 - 4 . 8 - 1 . 9 - 2 . 2 P681H 2 . 0 1 . 5 2 . 5 3 . 1 2 . 3 - 1 . 0 1 . 6 - 1 . 4 - 1 . 9 1 . 3 - 1 . 2 2 . 9 - 1 . 5 - 2 . 8 1 . 1 - 4 . 7 - 1 . 2 1 . 8 T716I 4 . 3 3 . 9 3 . 9 3 . 1 3 . 5 2 . 0 3 . 6 - 1 . 1 - 1 . 6 1 . 2 - 1 . 6 2 . 9 - 3 . 5 - 5 . 5 MPI↓ - 2 . 6 1 . 2 - 1 . 0 S982A - 3 . 9 - 3 . 0 - 2 . 4 1 . 1 - 2 . 0 1 . 4 - 2 . 3 - 2 . 2 - 1 . 2 1 . 6 - 1 . 0 - 1 . 5 - 1 . 1 - 1 . 1 - 2 . 9 - 4 . 3 1 . 2 - 1 . 3 D1118H - 1 . 1 - 3 . 1 1 . 0 1 . 2 1 . 0 1 . 7 - 1 . 3 - 1 . 4 - 1 . 7 1 . 2 1 . 5 1 . 1 - 1 . 3 - 3 . 1 1 . 4 - 1 . 1 - 1 . 1 - 1 . 8 SA B . 1 . 351 - 2 . 1 1 . 0 - 456 . 6 < - 1000 < - 1000 < - 1000 < - 1000 1 . 1 - 3 . 5 1 . 0 - 2 . 2 - 5 . 2 < - 1000 < - 1000 < - 1000 - 456 . 4 - 595 . 2 - 84 . 8 SAΔ9 - 2 . 0 1 . 3 < - 1000 < - 1000 < - 1000 < - 1000 - 58 . 8 1 . 3 1 . 8 1 . 2 1 . 3 3 . 3 < - 1000 < - 1000 < - 1000 - 406 . 6 < - 1000 - 18 . 1 L18F 1 . 5 1 . 9 2 . 8 3 . 0 1 . 0 1 . 8 1 . 4 - 1 . 4 - 1 . 8 1 . 1 1 . 2 - 1 . 6 - 2 . 2 1 . 3 MPI↓ - 107 . 2 < - 1000 - 8 . 9 D80A - 1 . 4 1 . 2 2 . 1 2 . 0 1 . 5 2 . 0 1 . 4 - 2 . 2 - 2 . 2 1 . 0 2 . 2 - 2 . 7 2 . 3 2 . 0 - 1 . 0 - 2 . 0 < - 1000 - 9 . 8 D215G 1 . 9 1 . 6 1 . 5 1 . 8 1 . 5 2 . 1 1 . 5 - 1 . 8 - 2 . 1 - 1 . 2 1 . 0 2 . 2 - 1 . 1 - 1 . 8 - 2 . 3 - 6 . 0 1 . 1 1 . 1 242 - 244del - 1 . 4 1 . 2 - 1 . 2 1 . 4 - 1 . 1 1 . 1 1 . 0 - 1 . 2 - 3 . 2 1 . 8 1 . 2 - 1 . 3 < - 1000 < - 1000 < - 1000 < - 1000 < - 1000 - 20 . 7 R246I 1 . 3 1 . 7 2 . 2 2 . 4 1 . 4 2 . 1 2 . 2 1 . 4 - 2 . 1 1 . 1 2 . 3 1 . 7 < - 1000 < - 1000 < - 1000 - 2 . 8 < - 1000 - 9 . 2 K417N 3 . 2 3 . 3 < - 1000 3 . 3 8 . 4 1 . 2 - 13 . 1 2 . 1 - 1 . 2 2 . 9 1 . 6 7 . 8 2 . 9 - 1 . 6 1 . 7 - 1 . 5 1 . 2 - 1 . 2 E484K - 1 . 2 - 1 . 0 4 . 3 < - 1000 < - 1000 < - 1000 - 10 . 5 - 3 . 4 - 1 . 1 2 . 3 2 . 5 - 1 . 1 - 1 . 6 - 3 . 2 MPI↓ - 2 . 8 - 1 . 1 - 1 . 4 N501Y - 1 . 2 - 1 . 4 - 12 . 7 1 . 5 - 1 . 0 1 . 5 - 1 . 4 - 1 . 0 1 . 3 1 . 2 1 . 2 3 . 6 - 2 . 9 - 6 . 7 MPI↓ - 12 . 0 - 1 . 4 - 3 . 2 A701V 1 . 9 1 . 4 2 . 1 2 . 8 2 . 0 1 . 6 2 . 3 - 1 . 8 - 2 . 6 1 . 5 1 . 1 2 . 5 - 3 . 3 - 2 . 0 MPI↓ - 3 . 3 - 1 . 2 - 1 . 3 NTD 69 - 70 L18 242 - 244 Y144 N1 14 - 26 N2 67 - 79 N3 141 - 156 R246 N5 246 - 260 NTD - directed antibodies RBD Y53 HC S56 HC E484K CDRH2 REGN10933 RBD R50 HC E484K LY - CoV555 Y101 HC Changes in IC50 of authorized or investigational therapeutic mAbs against B . 1 . 1 . 7 and B . 1 . 351 as well as UK∆8 and SA∆9 relative to the WT B . 1 . 1 . 7 WA1 B . 1 . 351 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 I C 50 (  g / m L ) UKΔ8 D614G SAΔ9 LY - CoV555 REGN10933 + 10987 LY - CoV555 + CB6 S309 Brii - 196 + Brii - 198 COV2 - 2196 + 2130 Authentic viruses Pseudoviruses Changes in neutralization IC50 of convalescent plasma against B . 1 . 1 . 7 and B . 1 . 351 relative to the WT No protection against re - infection in SA in Novavax placebos From Lancet 2021 Changes in neutralization activity of vaccinee sera against B . 1 . 1 . 7 and B . 1 . 351 Novavax protective efficacy WT 96 % B . 1 . 1 . 7 86 % B . 1 . 351 49 % J & J protective efficacy U . S . 72 % Latin Am 66 % SA 57 % - 8 . 6X * * * p < 0 . 001 - 1 . 8X * * p = 0 . 003 UKΔ8 D614G SAΔ9 10 2 10 3 10 4 10 5 10 6 - 12 . 4X * * * p < 0 . 001 1 . 6X p = 0 . 064 B . 1 . 1 . 7 WA1 B . 1 . 351 10 2 10 3 10 4 10 5 10 6 Moderna - 10 . 3X * * p = 0 . 002 1 . 3X p = 0 . 322 B . 1 . 1 . 7 WA1 B . 1 . 351 Pfizer R ec i p r o ca l se r u m I C 5 0 t i t e r i n p se udo v i r u s ass ay - 6 . 5X * * p = 0 . 002 - 2 . 0X * * p = 0 . 004 UKΔ8 D614G SAΔ9 R ec i p r o ca l se r u m I C 50 t i t e r i n a u t h e n t i c v i r u s assay W T B Z  1 0 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 I C 50 (  g / m L ) R E G N 10987 R E G N 10933 L Y - C o V 555 CB 6 W T B Z  1 0 21962130 2 - 36 2 - 15 C 1212 - 7 1 - 57 S 309 E UA O t h e r s W T B Z  1 0 5 - 24 4 - 18 2 - 17 4 - 19 4 - 8 5 - 7 - 6 . 5 X * * * p < 0 . 0001 W T B Z  10 10 2 10 3 10 4 10 5 R ec i p r o ca l se r u m I D 50 - 2 . 8 X * * * p = 0 . 0005 W T B Z  10 M od e r n a - 2 . 2 X * * p = 0 . 0020 W T B Z  10 P f i z e r RBD N T D M on o c l on a l A n t i bod i es C on va l esce n t P l as m a V acc i n ee S e r a a b To t a l = 1273 LegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegendLegend NTD RBD SD1 SD2 FP HR1 CH CT HR2 1 14 306 331 528 591 686 816 9 10 9 85 103 5 106 8 116 3 121 1 127 3 S1 S2 SA L18F UK 69 - 70del 144del N501Y A570D P681H T716I S982A D1118H D80A D215G 242 - 244del R246I K417NE484K A701V N501Y CD 782 - 814 680 - 744 BZ L18FT20NP26S D138Y R190S K417T E484K N501Y H655Y T1027I Antibody resistance of P . 1 ( BZ ) variant Wang et al https : / / www . biorxiv . org / content / 10 . 1101 / 2021 . 03 . 01 . 433466v1 A new SARS - CoV - 2 variant in the NY metropolitan area Hiroshi Mohri Medini Annavajhala Anne - Catrin Uhlemann Past week 36 % https : / / www . medrxiv . org / content / 10 . 1101 / 2021 . 02 . 23 . 21252259v1 ee s a e B . 1 . 1 . 7 ( 6 ) P . 2 ( 2 ) B . 1 . 351 ( 1 ) B . 1 . 526 ( > 70 ) ee s a e SARS - COV - 2 variant of concern identified in New York : B . 1 . 526 with E484K mutation Spike mutations found in B . 1 . 526 / E484K and resistance to antibody neutralization E484K T95I D253G A701V D614G NTDRBDS1 ( other regions ) S2N - linked glycan mAbs with EUA Convalescent plasma Vaccinee sera B . 1 . 1 . 7 is becoming dominant in most parts of US but it is out - competed by B . 1 . 526 in NYC E484K doubling time : ~ 12 days NYC DOH : 39 % B . 1 . 526 12 % B . 1 . 1 . 7 From NY Times